VI

Vimta Labs LtdNSE VIMTALABS Stock Report

Last reporting period 31 Mar, 2024

Updated 31 Oct, 2024

Last price

Market cap $B

0.074

Micro

Exchange

XNSE - National Stock Exchange Of India

VIMTALABS.NS Stock Analysis

VI

Avoid

Based on Eyestock quantitative analysis, VIMTALABS.NS`s fundamental data and valuation indicate an investment grade of Avoid at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

103/100

High score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

-40.4 %

Greatly overvalued

Market cap $B

0.074

Dividend yield

0.39 %

Shares outstanding

22.171 B

Vimta Labs Ltd. engages in the provision of contract research and testing. The company is headquartered in Hyderabad, Telangana and currently employs 1,368 full-time employees. The firm is engaged in providing a range of services to biopharmaceutical, food, consumer goods, electronic, electrical, agrochemical, healthcare, medical device, power, cement, oil and gas, ores and minerals, infrastructure and many other industries, government organizations as well as other industry participants. Its services include Drug discovery, development, and drug life cycle management support services; Preclinical research and testing services for medical device companies; Contract research and testing for agrochemical and specialty chemical companies; and Food testing and analytical development services to support manufacturers, processors, farmers, and retailers; Clinical diagnostics services to patients, clinicians, and hospitals, and environmental regulatory services such as impact assessments and post project monitoring, to various industries, such as power and infrastructure.

View Section: Eyestock Rating